Arbe Robotics Ltd. (NASDAQ: ARBE; TASE: ARBE) is a Tel Aviv–headquartered imaging-radar chip and full-system company that has spent most of its public life as a Tier 1–dependent automotive R&D story. The second quarter of fiscal 2026 is the first full quarter in which that story actually moved: Q2 revenue of $0.703 million was more than double the year-ago quarter's $0.274 million, and the first half of 2026 booked $1.164 million against $0.314 million in H1 2025 - nearly a fourfold lift, however modest the absolute dollars. That growth came from exactly the strategy management set out in February: a pivot from being a pure chipset supplier to becoming a full radar-systems provider, opening direct sales into defense, homeland security, perimeter security, and robotaxi alongside the slower-burning automotive Tier 1 pipeline. New defense shipments began, robotaxi platforms with Arbe radar reached on-road trials, Tier 1 HiRain confirmed a Chinese production start for the beginning of 2027, and the Tier 1 Sensrad signed a new commercial collaboration. The pivot is working in the literal sense - orders are converting into shipped product.
The other half of the quarter is the one the market is staring at. Operating loss still ran at $9.834 million for the quarter, the GAAP net loss was $9.094 million, and operating cash burn came in at $11.931 million - well above the revenue line, as it must be at this stage. Cash, cash equivalents and short-term bank deposits stood at $41.918 million at June 30, 2026, against a $24.0 million convertible bond due May 30, 2028, with a $1.0 million backlog and a reaffirmed 2026 outlook of $4–6 million in revenue and an adjusted EBITDA loss of $28–31 million. At that burn, runway through the convertible bond's escrow release is plausible but not generous, and the stock traded at $0.75 on the last day before this report - below the Nasdaq $1.00 minimum bid for roughly half a year. Listing risk is a current, active constraint, and a delisting from Nasdaq would cross-default the bonds. The thesis is no longer "does the technology work." The thesis is "do the pipeline conversions land in time, and on a Nasdaq-compliant listing."
The investment case for ARBE is therefore a transition bet with two clocks. The first clock is the HiRain L4 OEM production start in China, currently planned for the beginning of 2027, executing against a 340,000-chipset preliminary order. The second clock is the Nasdaq minimum-bid cure period and the company's own ability to meet the listing standard or to obtain shareholder approval for a reverse stock split, with the convertible bond holder remedy structure sitting in the background. The numbers that follow in this report - the revenue acceleration, the cost discipline, the cash position, the operating burn, the listing overhang - are the inputs to that judgment. Nothing about this quarter is hidden; everything about it is small, and what management is selling is the slope, not the level.